Zymeworks Inc. Common Stock Asset Resilience Ratio

Latest as of September 2025: 47.10%

Zymeworks Inc. Common Stock asset resilience ratio. Zymeworks Inc. Common Stock (ZYME) has an Asset Resilience Ratio of 47.10% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zymeworks Inc. Common Stock (ZYME) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$187.10 Million
Cash + Short-term Investments

Total Assets

$397.27 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Zymeworks Inc. Common Stock (2015–2024)

Asset resilience ratio of Zymeworks Inc. Common Stock from 2015 to 2024. This chart shows how Zymeworks Inc. Common Stock's Asset Resilience Ratio has changed over time. Read debt load of Zymeworks Inc. Common Stock for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Zymeworks Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zymeworks Inc. Common Stock balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $187.10 Million 47.1%
Total Liquid Assets $187.10 Million 47.10%

Asset Resilience Insights

  • Very High Liquidity: Zymeworks Inc. Common Stock maintains exceptional liquid asset reserves at 47.10% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Zymeworks Inc. Common Stock Industry Peers by Asset Resilience Ratio

Compare Zymeworks Inc. Common Stock's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Zymeworks Inc. Common Stock Asset Resilience Ratio by Year (2015–2024)

Zymeworks Inc. Common Stock asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Zymeworks Inc. Common Stock.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 34.48% $159.67 Million $463.09 Million -2.84pp
2023-12-31 37.32% $216.77 Million $580.88 Million +23.24pp
2022-12-31 14.08% $91.32 Million $648.73 Million +1.04pp
2021-12-31 13.04% $50.74 Million $389.13 Million -21.20pp
2020-12-31 34.24% $184.32 Million $538.38 Million -12.06pp
2019-12-31 46.29% $170.45 Million $368.20 Million -18.35pp
2018-12-31 64.64% $157.96 Million $244.36 Million +25.35pp
2017-12-31 39.29% $51.85 Million $131.96 Million +13.95pp
2016-12-31 25.35% $23.82 Million $94.00 Million +9.62pp
2015-12-31 15.73% $3.64 Million $23.15 Million --
pp = percentage points

About Zymeworks Inc. Common Stock

NASDAQ:ZYME USA Biotechnology
Market Cap
$2.32 Billion
Market Cap Rank
#6340 Global
#2020 in USA
Share Price
$30.94
Change (1 day)
+2.69%
52-Week Range
$16.46 - $31.05
All Time High
$56.81
About

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more